Tango Therapeutics (NASDAQ:TNGX) Posts Earnings Results, Misses Estimates By $0.02 EPS

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.02), Zacks reports. Tango Therapeutics had a negative return on equity of 49.64% and a negative net margin of 284.42%.

Tango Therapeutics Stock Up 1.8%

NASDAQ TNGX opened at $1.12 on Monday. The company has a market cap of $121.08 million, a price-to-earnings ratio of -0.95 and a beta of 1.02. Tango Therapeutics has a 52 week low of $1.03 and a 52 week high of $12.02. The business has a 50 day moving average price of $1.51 and a 200-day moving average price of $2.66.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a "buy" rating and set a $13.00 price objective on shares of Tango Therapeutics in a research report on Monday, April 14th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $12.33.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.